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Supplementary Table 1. Numbers of cases and controls from each study that were part of this GWAS. 
Number of Subjects1Study Name Study abbreviation 
Study 
population Study type cases controls 
STAGE1 
SEARCH Cambridge UK SEA UK Population based 1156 (36) - 
UKOPS (United Kingdom Ovarian 
Cancer Population Study) UKO UK Population based 522 (16) - 
Cancer Research UK familial 
ovarian Cancer Register FOCR UK 
Familial cancer 
register 47 (3) - 
Royal Marsden Hospital study RMH UK Hospital based 165 (18) - 
UK 58 Birth cohort 58 BC UK Cohort - 1436 
UK Colorectal control NSCR UK Population based - 917 
Subtotal 1890 (73) 2353 
STAGE 2 
Australian Cancer Study (ovarian 
cancer); Australian Ovarian Cancer 
Study 
AUS Australia Population based 1139 (5) 1166 (5) 
Diseases of the Ovary and their 
Evaluation Study DOVE 
Washington 
State, USA Population based 794 (1) 799 (1) 
Polish Ovarian Cancer Study (1) POL1 Poland Population based 555 (35) 517 (10) 
Los Angeles County Case-Control 
Studies of Ovarian Cancer USC 
Los Angeles, 
USA Population based 541 (4) 600 (79) 
Malignant Ovarian Cancer study MAL Copenhagen, Denmark Population based 446 (1) 556 (5) 
Gilda Radner familial ovarian 
cancer register GR Buffalo, USA 
Familial cancer 
register 121 - 
Hormones and ovarian cancer 
prediction study HOP Pittsburgh, USA Population based 392 (1) 396 (1) 
Genetic Epidemiology of Ovarian 
Cancer STA Stanford, USA Population based 297 (2) 417 (1) 
UKOPS (United Kingdom Ovarian 
Cancer Population Study) UKO UK Population based 212 466 
Polish Ovarian Cancer Study (2) POL2 Warsaw & Lodz Poland Population based 238 228 
Bavarian ovarian cancer study BAV Germany Population based 229 (82) 234 (40) 
Subtotal 4964 (131) 5379 (142) 
STAGE 3 
New England case-control study of 
ovarian cancer NEC 
New Hampshire 
and eastern 
Massachusetts, 
USA 
Population based 717 1049 
UC Irvine Ovarian Cancer Study, 
California UCI California, USA Population based 329 528 
Mayo Clinic Ovarian Canver Study MAY Upper Midwest, USA Clinic based 376 533 
North Carolina Ovarian Cancer 
Study NCO 
North Carolina, 
USA Population based 279 353 
Hawaii Ovarian Cancer Study HAW Hawaii, USA Population based 355 650 
Hannover-Jena Ovarian  
 Cancer Study HJOCS Germany Hospital based 271 1012 
Familial ovarian tumour study TOR Canada Population based 301 294 
German Ovarian Cancer Study GER Germany Population based 219 433 
Nurses’ Health Study, Boston NHS USA Population based 115 380 
Melbourne Collaborative Cohort 
Study MCCS Australia Cohort 127 108 
Subtotal 3089 5340 
TOTAL 9943 (204) 13072 (142)
1 The numbers of subjects that were excluded in analysis because of not passing genotyping quality control 
criteria are presented in brackets. 
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Supplementary Table 2. Summary results for the 12 genome wide significant SNPs at 9p22.2 based on 
stage 1 and stage 2 data for subjects of European ancestry. 
Id SNPs Base change1
Chr9 
position2
SNP relative to 
BNC2 Gene MAF
3 LD4 Per-allele OR 95%CI 5 P-trend 
1 rs3814113 T/C 16905021 ~44kb upsteam 0.31 1.0 0.79 (0.75-0.84) 2.47x10-17
2 rs4445329 G/A 16901757 ~41kb upstream 0.31 1.0 0.79 (0.75-0.84) 2.67x10-17
3 rs10810666 C/T 16901666 40.9kb upstream 0.19 0.74 0.80 (0.75-0.85) 1.24x10-12
4 rs10962656 G/A 16867788 7kb upstream 0.14 0.59 0.81 (0.76-0.87) 5.88x10-9
5 rs12379183 A/G 16855699 Intron 2 0.22 0.71 0.82 (0.78-0.87) 1.36x10-10
6 rs2153271 A/G 16854521 Intron 2 0.41 0.77 0.85 (0.81-0.90) 4.66x10-10
7 rs7861573 G/A 16852280 Intron 2 0.22 0.70 0.83 (0.78-0.88) 3.61x10-10
8 rs10756819 A/G 16848084 Intron 2 0.33 0.83 0.83 (0.79-0.88) 4.85x10-12
9 rs1416742 T/C 16846883 Intron 2 0.4 0.74 0.86 (0.82-0.90) 1.74x10-9
10 rs12379687 G/T 16844367 Intron 2 0.15 0.57 0.82 (0.77-0.88) 1.27x10-8
11 rs4961501 G/T 16841678 Intron 2 0.23 0.72 0.82 (0.77-0.87) 8.49x10-12
12 rs1339552 G/A 16838790 Intron 2 0.41 0.76 0.85 (0.81-0.89) 1.28x10-10
1 The most common allele in controls is given first,  2  genome build NCBI B36 assembly.  3 MAF: minor allele 
frequency in ovarian cancer controls,  4 pairwise correlation (r2) between associated SNPs with rs3814113 in European 
control subjects. 5 Per rare allele Odds ratios with 95% confidence interval are presented. 
Supplementary Table 3: Ovarian cancer risks for the rs3814113 SNP by ancestry group in combined 
analysis. 
Ethnic group No. cases /controls Per allele OR 95%CI P-trend 
All 9739/12931 0.82 (0.79-0.86) 2.47x10-19
European 8761/11831 0.82 (0.79-0.86) 5.10x10-19
African 52/67 0.54 (0.29-0.99) 0.048 
Asian 237/296 0.83 (0.63-1.10) 0.19 
Other 378/292 0.87 (0.70-1.07) 0.19 
Data highlighted with bold text are GWAS significant (P<5.0x10-8) 
Supplementary Table 4: Ovarian cancer risks for the rs3814113 SNP after stratification by histological 
subtype in combined analysis for subjects of European ancestry. 
Tumor subtype No. cases /controls Per allele OR 95%CI P-trend 
All types 8761/11831 0.83 (0.79-0.86) 5.10x10-19
Serous 4847/11831 0.77 (0.73-0.81) 4.10x10-22
Mucinous 626/11831 0.97 (0.86-1.09) 0.60 
Endometrioid 1320/11831 0.86 (0.79-0.97) 0.001 
Clear cell 628/11831 0.94 (0.83-1.07) 0.34 
Other1 1226/11831 0.83 (0.76-0.91) 6.6x10-5
1 Other: included all the invasive epithelial ovarian cancer cases except serous, mucinous, endometrioid and 
clear cell ovarian cancer subtypes. Data highlighted with bold text are GWAS significant (P<5.0x10-8) 
Supplementary Table 5: Ovarian cancer risks for the rs3814113 SNP by age in combined analysis for 
subjects of European ancestry. 
Tumor subtype <40 40-49 50-59 >60 P-trend1
Overall 1.12 (0.93-1.36) 0.83 (0.75-0.91) 0.82 (0.74-0.89) 0.80 (0.73-0.85) 0.006 
Serous 1.05 (0.81-1.37) 0.76 (0.67-0.86) 0.81 (0.73-0.91) 0.76 (0.70-0.83) 0.044 
1 Test for trend on the OR by age, fitting a linear interaction term in logistic regression. 
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Supplementary Table 6: Comparison of the notable results from candidate gene studies with the results 
from this GWAS 
SNP Gene/locus Reported
a 
OR 
Reporteda 
P-value 
Reference GWASb 
OR 
GWASb 
P-value 
rs4954956c NXPH2 1.14 0.00017 Song et al, 2009 20 0.99 0.84 
rs11683487d NMI 0.87 0.032 Quaye et al., 2009 21 0.86 0.027 
rs2740574 CYP3A4 2.81 0.017 Pearce et al., 2009 22 1.19 0.16 
rs2287498c TP53 1.30 0.0059 Schildkraut et al., 2009 23 1.03 0.78 
rs12951053c TP53 1.20 0.056 Schildkraut et al., 2009 23 1.05 0.66 
rs2854344 RB1 0.88 0.041 Ramus et al., 2008 24 0.88 0.15 
rs2273535 AURKA 1.10 0.027 Ramus et al., 2008 24 1.01 0.84 
rs10505477 8q24 1.14 0.002 Ghoussaini et al., 2008 25 1.10 0.03 
rs10808556 8q24 1.13 0.0017 Ghoussaini et al., 2008 25 1.11 0.02 
rs6983267 8q24 1.11 0.0099 Ghoussaini et al., 2008 25 1.10 0.04 
rs2660753 3p12 1.19 0.012 Song et al., 2008 26 1.05 0.53 
rs3731257 CDKN2A 0.91 0.008 Gayther et al., 2007 27 0.97 0.89 
rs2066827 CDKN1B 0.93 0.036 Gayther et al., 2007 27 1.02 0.76 
rs2191249 BRIP1 0.90 0.045 Song et al, 2007 28 0.87 0.01 
rs4988344 BRIP1 1.15 0.02 Song et al, 2007 28 0.95 0.42 
a – reported per-allele OR and trend test unless otherwise indicated 
b - results from Stage 1 under same genetic model as published data. 
c – serous subtype only 
d – dominant model 
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Supplementary figure 1: Quantile-quantile plots for the test statistics for 
Stage 1 and Stage 2 analyses
Quantile-quantile plots for the test statistics (Chi squared Cochran-Armitage 1 d.f. )  for (a) Stage 1
 and (b) Stage 2  restricted to subjects of European ancestry.  Under the null hypothesis of no 
association at any locus, the points would be expected to follow the black line. 
